| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $22.0M | -40.8% | -19.4% |
| SG&A Expense | $4.5M | -1.7% | -9.4% |
| Operating Income | -$26.5M | +36.5% | +17.8% |
| Net Income | -$26.5M | +35.4% | +11.1% |
| EPS (Basic) | -$0.44 | +35.3% | +12.0% |
| EPS (Diluted) | -$0.44 | +35.3% | +12.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $46.8M | +27.2% | +41.1% |
| Short-term Investments | $79.8M | -25.1% | -52.3% |
| Current Assets | $132.2M | -11.0% | -36.4% |
| Total Assets | $142.2M | -17.3% | -46.7% |
| Current Liabilities | $22.0M | -11.7% | +10.3% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$96.4M | — | — |
| Investing Cash Flow | $107.7M | — | — |
| Financing Cash Flow | -$36K | — | — |
| $27.1M |
| -9.5% |
| -8.8% |
| Total Liabilities | $49.0M | -10.5% | -1.5% |
| Stockholders' Equity | $93.2M | -20.4% | -57.1% |